Davis Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Davis Capital Management's ACAD Position: Q3 2026 in Review
Davis Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 71% in Q3 2026, buying an estimated $134 and bringing the position to 12 shares worth $242. The position accounts for ﹤0.01% of the portfolio, ranked #817.
Davis Capital Management first reported a position in ACAD in Q2 2026 and has held it in 2 quarters since. 346 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Davis Capital Management held 12 shares of Acadia Pharmaceuticals worth $242 as of Q3 2026.
- Davis Capital Management bought 5 Acadia Pharmaceuticals shares in Q3 2026, an estimated $134.
- Acadia Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #817 holding.
- Davis Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
- 346 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.